share_log

Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals

Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals

坎託·菲茨傑拉德重申增持ORIC製藥
Benzinga ·  05/28 09:13

Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.

康泰福克蘭分析師Prakhar Agrawal重申oric Pharmaceuticals(納斯達克: oric pharmaceuticals)爲超額配重。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論